GISD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$63.07 |
52 Week High | US$79.42 |
52 Week Low | US$63.07 |
Beta | 0.20 |
1 Month Change | -6.48% |
3 Month Change | -14.38% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -10.42% |
Recent News & Updates
Recent updates
Shareholder Returns
GISD | GB Biotechs | GB Market | |
---|---|---|---|
7D | -0.6% | -0.2% | 2.3% |
1Y | n/a | -29.5% | 0.6% |
Return vs Industry: Insufficient data to determine how GISD performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how GISD performed against the UK Market.
Price Volatility
GISD volatility | |
---|---|
GISD Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: GISD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GISD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GISD fundamental statistics | |
---|---|
Market cap | €78.16b |
Earnings (TTM) | €5.29b |
Revenue (TTM) | €25.34b |
14.8x
P/E Ratio3.1x
P/S RatioIs GISD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GISD income statement (TTM) | |
---|---|
Revenue | US$27.12b |
Cost of Revenue | US$6.02b |
Gross Profit | US$21.10b |
Other Expenses | US$15.43b |
Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 4.54 |
Gross Margin | 77.80% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 109.8% |
How did GISD perform over the long term?
See historical performance and comparison